Q-omics provides the consensus-scored SNORA22B profile across patient tissues and cancer cell-line models. SNORA22B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SNORA22B is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, SNORA22B RNA expression shows 14,554 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KICH, HNSC, and TGCT as cancer lineages where SNORA22B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA22B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA22B survival associations across molecular data types. SNORA22B RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA22B RNA expression–survival associations across cancer types. High SNORA22B expression shows unfavorable associations in KICH, LGG, STAD and MESO, but favorable associations in UCS and BRCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for SNORA22B RNA expression.
This table summarizes SNORA22B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA22B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA22B shows higher tumor expression in HNSC, LUSC, STAD, READ, CHOL and COAD. The HNSC box plot shows higher SNORA22B RNA expression in tumor versus normal tissue (log2 FC = +0.532, t-test p = .004).
This table shows molecular features associated with SNORA22B in patient tissues and cancer cell lines. In patient samples, SNORA22B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
